On Dec. 29, 2020, the U.S. Department of Defense (DOD) announced that the Womack Army Medical Center was the latest DOD location to join Phase 3 SARS-CoV-2 vaccine trials. This location had been identified to participate in the Phase 3 clinical trial evaluating the safety and efficacy of the Novavax vaccine candidate NVX-CoV2373.

The Phase 3 clinical trial design is harmonized with those of other leading companies and calls for the enrollment of up to 30,000 participants in the U.S. and Mexico.